Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label anakinra study in NOMID/CINCA
2013-000300-42Phase 2
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Jan 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anakinra in neonatal-onset multisystem inflammatory disease (NOMID), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Primary endpoint: Change in disease symptom severity score.
02
Drugs
anakinra
03
Conditions
neonatal-onset multisystem inflammatory disease (NOMID)
Beyond the preview
Go deeper on 2013-000300-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000300-42.